Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

-

RAC Letter - MebHibrix

 

Our STN: BL 125363/0
 
GlaxoSmithKline Biologicals
Attention:  Jody Gould, Ph.D.
2301 Renaissance Blvd.
P.O. Box 61540
King of Prussia, PA 19406
 
Dear Dr. Gould:
 
We have received your April 15, 2011, resubmission to your biologics license application for Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine, for active immunization of infants and toddlers 6 weeks through 15 months of age for the prevention of invasive diseases caused by Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y on April 15, 2011.
 
We consider this a complete, Class 2 response to our action letter. Therefore, the user fee goal date is October 15, 2011.
 
If you have any questions, please contact the Regulatory Project Manager, CDR David Staten, at (301) 796-2640.
 
Sincerely yours,
 
 /s/
 
Wellington Sun, M.D.
Director
Division of Vaccines and
Related Product Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research
 

 

-
-